A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.

NCT Number	NCT07540754
Lead Sponsor	Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions	Diabetes Mellitus, Weight Loss
Enrollment	24 participants
Start Date	2026-05-26
Primary Completion	2027-01 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-01